Niagen Bioscience Inc (NAGE) P/E Ratio History
Deep ValueTrading at 17.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Niagen Bioscience Inc (NAGE) trades at a price-to-earnings ratio of 17.1x, with a stock price of $3.42 and trailing twelve-month earnings per share of $0.22.
The current P/E is 73% below its 5-year average of 62.9x. Over the past five years, NAGE's P/E has ranged from a low of 20.2x to a high of 193.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, NAGE trades at a 26% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, NAGE trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NAGE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NAGE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NAGE P/E vs Peers
Metabolic and Obesity Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 29.3 | 1.27 | -25% | |
| $17B | 36.1 | 15.42 | +42% | |
| $193B | 25.2 | 8.56 | +88%Best | |
| $138B | 17.9 | - | -4% | |
| $317B | 17.6Lowest | 0.83Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NAGE Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $4.41 | $0.22 | 20.2x | -68% |
| FY2025 Q4 | Dec 31 2025 | $6.36 | $0.20 | 31.1x | -51% |
| FY2025 Q3 | - | $9.33 | $0.24 | 38.3x | -39% |
| FY2025 Q2 | Jun 30 2025 | $14.41 | $0.21 | 67.1x | +7% |
| FY2025 Q1 | Mar 31 2025 | $6.90 | $0.17 | 40.0x | -36% |
| FY2024 Q4 | - | $5.31 | $0.11 | 50.4x | -20% |
| FY2024 Q3 | Sep 30 2024 | $3.65 | $0.02 | 193.1x | +207% |
Average P/E for displayed period: 62.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NAGE — Frequently Asked Questions
Quick answers to the most common questions about buying NAGE stock.
What is NAGE's P/E ratio?
Niagen Bioscience Inc (NAGE) trailing twelve-month P/E ratio is 17.1x, based on TTM diluted EPS of $0.22. The 5-year average P/E is 62.9x and the historical range spans 20.2x to 193.1x.
Is NAGE stock overvalued or undervalued?
NAGE trades at 17.1x P/E, below its 5-year average of 62.9x. At the 0th percentile of its historical range (20.2x–193.1x), the stock is priced at a discount to its own history.
Is NAGE stock expensive?
No, NAGE is not expensive on a historical basis. The current P/E of 17.1x is below the 5-year average of 62.9x and sits at the 0th percentile of its valuation range.
What is NAGE's historical P/E range?
Over the past 5 years, NAGE's P/E ratio has ranged from 20.2x to 193.1x, with a median of 40.0x and an average of 62.9x. The current P/E of 17.1x places the stock at the 0th percentile of this range. Full historical data spans 2024–2026.
How does NAGE's P/E compare to the S&P 500?
NAGE trades at 17.1x P/E versus the S&P 500 median of 25.3x. The 32% discount to the market suggests lower growth expectations or perceived higher risk.
How does NAGE's valuation compare to Healthcare peers?
Niagen Bioscience Inc P/E of 17.1x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NAGE's PEG ratio?
NAGE PEG ratio is N/A, based on a P/E of 17.1x and EPS growth of 81.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NAGE's earnings yield?
NAGE earnings yield is 5.85%, the inverse of its 17.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.